Newsroom 2006
Attention Business/Financial Editors:
Neurochem to present at UBS Global Specialty Pharmaceuticals Conference and at 6th Annual Fortis Bank Biotechnology Conference
LAVAL, QC, April 20 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX:
NRM) announced today that on Tuesday, April 25, 2006, Dr. Francesco Bellini,
Chairman, President and CEO, will present Neurochem's overall strategy and
progress to date at the UBS Global Specialty Pharmaceuticals Conference to be
held at the Grand Hyatt New York, in New York (N.Y.). The presentation will
take place at 10:30 A.M. ET, in Ballroom C. Following Dr. Bellini's speech,
the corporate presentation will be available on the Company's website at
http://www.neurochem.com/Investor.htm#Presentation.
A live audio Web cast of Neurochem's presentation can be accessed at
www.ibb.ubs.com. A replay of the presentation will begin 3 hours after the
actual presentation time, and will be available until May 25, 2006.
Dr. Bellini will also present an update on the Company's activities at
the Sixth Annual Fortis Bank Biotechnology Conference on Wednesday, April 26,
2006, at The Four Seasons Hotel, Park Lane, in London (U.K.). The presentation
will take place at 11:15 A.M. GMT, in Ballroom A, and will be available on the
Company's website.
About Neurochem
Neurochem is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(Fibrillex(TM)) is designated as an orphan drug, is a Fast Track product
candidate and is also part of FDA Continuous Marketing Application Pilot 1 and
Pilot 2 programs. The FDA designated the eprodisate (Fibrillex(TM)) new drug
application for priority review. Tramiprosate (Alzhemed(TM)), for the
treatment of Alzheimer's disease, is currently in Phase III clinical trials in
both North America and Europe, and tramiprosate (Cerebril(TM)), for the
prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has
completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1-877-680-4500 or
visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, as well as other risks
disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the forward-
looking statements. The reader should not place undue reliance, if any, on the
forward-looking statements included in this news release. These statements
speak only as of the date made and Neurochem is under no obligation and
disavows any intention to update or revise such statements as a result of any
event, circumstances or otherwise. Please see the Annual Information Form for
further risk factors that might affect the Company and its business.
For further information: Lise Hébert, PhD, Vice President, Corporate
Communications, (450) 680-4573, lhebert@neurochem.com
